7 th NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF VIROLOGY

Size: px
Start display at page:

Download "7 th NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF VIROLOGY"

Transcription

1 7 th NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF VIROLOGY Orvieto (TR) Palazzo del Capitano del Popolo June 24-26,

2

3 COMMITEES President of the Congress Palù Giorgio Scientific Committee Franco Buonaguro Canio Buonavoglia Gabriella Campadelli-Fiume Francesco Maria Cancellotti Maurizio Conti Carlo De Giuli Morghen Antonina Dolei Giuseppe Gerna Colomba Giorgi Giorgio Gribaudo Maria Paola Landini Roberto Manservigi Giorgio Palù Maria Cristina Parolin Carlo Federico Perno Mauro Pistello Luisa Rubino Franco Maria Ruggeri Paola Verani Borgucci Maurizio Zazzi Organizing Committee Elisabetta Affabris Alberta Azzi Francesco Maria Cancellotti Colomba Giorni Anna Maria Iorio Franco Maria Ruggeri Cristiano Salata Eurovirology Travel Grant and poster-prize Committee Canio Buonavoglia Gabriella Campadelli-Fiume Antonina Dolei Giovanni Martelli Giorgio Palù 3

4 SECRETARIATS SCIENTIFIC SECRETARIAT SIV - Italian Society of Virology c/o Department of Histology, Microbiology and Medical Biotechnologies University of Padova - Italy The Italian Society of Virology is supported by ORGANIZING SECRETARIAT MZ CONGRESSI Member of the MZ International Group (Milano, Torino, Barcelona, London) Via Carlo Farini, Milano - Italy Phone Fax Speakers, chairs and companies: Patrizia Sirtori - Registrations: ACKNOWLEDGMENTS We thank the Comune di Orvieto for its continuous support. GENERAL INFORMATION OFFICIAL LANGUAGE The official language of the symposium is English CME Italian CME Credits have been assigned by the Italian Ministry of Health for the following categories: - Medical Doctor: 10 credits (Specialist Areas: Microbiology and Virology, Infectious Diseases, Pharmacology and Clinical Toxicology) - Biologist: 10 credits (Specialist Areas: Microbiology and Virology) - Biomedical Laboratory Technician: 11 credits Italian CME certificates will be sent after the Congress directly to the address indicated on the registration form. 4

5 PROGRAMME Sunday, 24 June : Registration 17:30 Opening and welcome Chair: Antonina Dolei (Sassari) 17:45 GB Rossi Lecture New aspects of interferon systems, immune evasion and new potential applications Filippo Belardelli (Roma) GENERAL VIROLOGY AND VIRAL GENETICS Chairs: Maurizio Conti (Torino), Maria Cristina Parolin (Padova) Selected oral presentations Increasing circulation and diversification of HIV-1 non-b subtypes in Italy over a 10- year observation period F. Razzolini Detection and quantification of noroviruses in environmental samples by newly designed nested PCR assays and Taqman Real-Time RT-PCR M. Muscillo UL products are required for the activation of HCMV fusion complex during endothelial cell infection M. Patrone Prevalence and Persistence of human papillomavirus genotypes and their variants in Human Immunodeficiency Virus (HIV) positive women from south-italy F.M. Buonaguro Polyomavirus BK and anti-dsdna antibodies in renal transplant recipients C. Costa Inconsistent responses of cytomegalovirus-specific T-cells to pp65 and IE-1 vs infected dendritic cells in organ transplant recipients D. Lilleri 5

6 Monday, 25 June 2007 MEDICAL VIROLOGY AND ANTIVIRAL THERAPY Chairs: Carlo Federico Perno (Roma), Maurizio Zazzi (Siena) KeyNote Lecture Antiviral strategies, mechanism, and clinical efficacy Massimo Puti (Brescia) 09: Selected oral presentations Human respiratory syncytial virus (hrsv) RNA quantification in nasopharyngeal secretions identifies the hrsv etiologic role in acute respiratory tract infections of hospitalized infants G. Campanini The human bocavirus role in acute respiratory tract infections of pediatric patients as defined by viral load quantification G. Gerna Antiviral activity of Retinoic Acid derivatives against HHV-8 E. Caselli Pre-transplant analysis of preservation and washing solutions for rapid detection of viruses in the kidney graft M. Pacenti Antiviral activity of WC5, a new 6-Aminoquinolone compound, against human herpesviruses B. Mercorelli BREAK VIRAL BIOTECHNOLOGIES AND GENE THERAPY Chairs: Giorgio Gribaudo (Torino), Giorgio Palù (Padova) Selected oral presentations Persistent viral detection in the kidney allograft is a risk factor for chronic allograft injury L. Barzon Viral clearance evaluation model using 4 different viruses for GMP-Production of biopharmaceutical drugs or vaccines JL. McDermott Effects of adenoviral vector infection on human adrenocortical cells U. Matkovic Role of recombinant poxvirus vectors expressing HIV/SIVgenes in modulating Th1/Th2 cytokine profiles in human dendritic cells P. Beggio 6

7 Human placenta derived mesenchymal stem cells are fully permissive to human cytomegalovirus infection L. Luconi Expression of the HPV-16 L1 Antigen in Transplastomic Tobacco Plants P. Lenzi 12: LUNCH VIRAL ONCOGENESIS AND VACCINES Chairs: Franco Buonaguro (Napoli), Colomba Giorgi (Roma) KeyNote Lecture New strategies in Vaccine Development The HIV experience Hans Wolf (Regensburg Germany) Selected oral presentations Anti-cancer activity of plant-produded HPV16 E7 vaccine S. Massa Development of a vaccine against Toscana Virus G. Gori Savellini Development of avipoxvirus recombinant vaccines for the control of HPV16-induced cervical cancer E. Pozzi Impact of the seropositivity status on the pattern of DC activation by Virus-Like Particles L. Buonaguro Distribution of human papillomavirus type 16 variants in penile keratinizing squamous cell carcinoma ML. Tornesello Expression, processing and assembly of the HIV-1 Pr55gag protein in transgenic tobacco chloroplasts N. Scotti BREAK 7

8 HPV INFECTION AND PREVENTION Chairs: Franco Buonaguro (Napoli), Colomba Giorni (Roma) HPV and HPV-associated diseases worldwide burden Kate Soldan (London UK) Characterisation of the interaction of HPV E6 with the Discs Large Tumour Suppressor Lawrence Banks (Trieste) VLPs: past and future Reinhard Kirnbauer (Vienna Austria) Gardasil Franco Scaglione (Milano) Long-term impact of prophylactic ant-hpv 16/18 vaccine Davis Jenkins (Rixensart Belgium) New therapeutic strategies Aldo Venuti (Roma) Tavola rotonda Panel discussion: issues and guidelines (in italiano) Coordinator Sergio Pecorelli (Brescia) La vaccinazione in Italia Maria Grazia Pompa (Roma) Metodi diagnostici e screening nell'era del vaccino Francesca Carozzi (Firenze) Il punto di vista del virologo Giorgio Palù (Padova), Carlo Federico Perno (Roma), MariaLina Tornesello (Napoli) Il punto di vista del ginecologo Aldo Vecchione (Napoli) Come controllare l'efficacia del vaccino, chi lo farà e come lo farà Marta Ciofi degli Atti (Roma) 8

9 Tuesday, 26 June KeyNote Lecture Virological monitoring of environmental matrices and food: importance for the risk assessment Annalaura Carducci (Pisa) VIRUS HOST INTERACTIONS AND PATHOGENESIS Chairs: Mauro Pistello (Pisa), Luisa Rubino (Bari) Selected oral presentations Down-regulation of proteolytic complexes following Epstein Barr Virus activation in Burkitt s lymphoma cells G. Matusali Analysis of HCMV ppul44 homodimerization, intra-nuclear mobility and phosphorylation-regulated nuclear transport using live cells imaging G. Alvisi Human cytomegalovirus replicates in adrenocortical cells and stimulates steroid hormone production M. Trevisan HSV-1 induces dysregulation of monocyte anticandida functions C. Cermelli What s the clue in the progression of liver damage during HCV-infection? Analysis of the role of HCV NS5A and Core proteins M. Marcolongo Involvement of the E62EEE65 Nef Acidic Domain and TRAF Family Members on Signaling Events Induced by treatment of Monocytes/Macrophages with HIV-1 Nef G. Mangino HPV infection in HIV positive subjects: 10 years experience of follow-up F. Lillo 10: BREAK 11: Guidelines for human Cytomegalovirus infections Giuseppe Gerna (Pavia) 11:45-12:45 Poster Session 12: LUNCH 9

10 EMERGING AND ZOONOTIC VIRAL INFECTIONS Chairs: Canio Buonavoglia (Bari), Franco Ruggeri (Roma) KeyNote Lecture An emerging zoonosis: European bat lyssaviruses Franco Mutinelli (Legnaro PD) 14: Selected oral presentations Emerging respiratory infections in hematopoietic stem cell-transplanted children in Germany V. Falcone Characterization of the biological properties of human and rhesus VP8* proteins F. Cappuccini Detection of norovirus in a captive lion cub with haemorrhagic enteritis (Panthera leo) V. Martella Virologic Characterization of a Poxvirus Zoonosis in Northern Italy F. Carletti 15:30-17:00 SOCIETY MEETING 17:00 Best Poster Award and Travel Awards for Eurovirology 2007 Closing remarks 10

11 GB Rossi & Keynote Lectures 11

12

13 New aspects of interferon systems, immune evasion and new potential applications Filippo Belardelli Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy. Half a century has passed since the discovery of interferons (IFNs) as antiviral factors released by virus-infected cells. The first two decades of IFN research were characterized by major difficulties in convincing the scientific community about the specificity of the emerging biological effects. In the early 1980s, when recombinant IFNs became available, it was recognized that this family of cytokines, comprising the type I or viral IFNs (mainly α and β) and the type II or immune IFN (γ), could also exert multiple activities on cell growth, differentiation and immune response. Today, in revisiting 50 years of history of IFN research, the impact of early studies on the IFN system appears to be impressive. IFNs-α are the cytokines with a longest record of clinical use and are still used in patients with certain malignancies and viral diseases, while IFN-β is currently used in patients with multiple sclerosis. Notably, IFN research has been instrumental for understanding cytokine signal transduction pathways and important mechanisms regulating antiviral, antitumor and immune responses. Recently, multiple mechanisms by which viruses can undermine the potent IFN-mediated host defence system have been described. These mechanisms are important for evading the direct IFNmediated control on viral replication as well as for allowing evasion from an effective immune response, which is also regulated by the IFN system. Likewise, immune suppression, linked to impaired IFN production or defective cytokine response, has been observed in cancer patients. These findings are consistent with data in mouse models, demonstrating: i) the importance of the integrity of the IFN system in the host immune surveillance against tumors; ii) the role of endogenous IFN in chemotherapy-induced reversion of immune suppression in tumor-bearing animals. Notably, recent studies have underscored new effects of IFNs (especially type I IFN) on cells of the immune system (including T cells and dendritic cells), which are important in linking innate and adaptive immunity. Thus, in mouse models, type I IFN can act as a powerful vaccine adjuvant by acting on dendritic cells (DCs). Likewise, DCs rapidly generated from human monocytes after exposure to IFN-α (IFN-DCs) act as powerful cellular adjuvants for the generation of MHC class I restricted CD8+ T cell responses against viral (HIV and EBV) and tumor (melanoma) antigens and efficiently crossprime CD8+ T cells against exogenous antigens. On the whole, the preclinical data suggest that these IFN-DCs exhibit some unique characteristics particularly suitable for the generation of effective DC-based vaccines. New therapeutic strategies can now be based on a novel rationale for using IFN-α, including the direct in vivo use of these cytokines as vaccine adjuvants and their in vitro use to generate highly active patient s monocyte-derived DCs to be utilized in therapeutic vaccination protocols. Such immunotherapy strategies are particularly suitable in patients showing immune suppression features (induced either by virus infection of by tumor progression) which can be effectively restored by IFN-induced immune interventions targeted to DCs and by additional combination treatments. Moreover, a detailed knowledge on the IFN system in patients with cancer and HCV-infection would be instrumental in selecting categories of patients responding to IFN therapy. Planned clinical studies are expected to provide evidence on the importance of IFN-DC interactions in patients and on the perspectives of this novel use of IFN-α in immunotherapy protocols. 13

14 Antiviral strategies, mechanism and clinical efficacy Massimo Puoti Le terapie antivirali negli ultimi tempi hanno assunto una crescente importanza in Clinica in virtù del loro impatto sulla sopravvivenza di soggetti con malattie virali croniche legato all'immediato efetto sulle loro sequele. L'impato dei farmaci antiretrovirali sulla sopravvivenza e sulla qualità di vita dei soggetti con AIDS è ben noto, ma recentemente l'impiego delle terapie anti HBV ed anti HCV ha consentito di ridurre la mortalità per cirrosi ed epatocarcinoma e l'impiego delle terapie anti CMV quella per le infezioni da CMV in soggetti immunodepressi. NEW STRATEGIES IN VACCINE DEVELOPMENT: THE HIV EXPERIENCE Prof. Dr. Hans Wolf University of Regensburg, Institute for Medical Microbiology and Hygiene In response to the growing problems related with HIV-infections in poor economics, industrialized countries responded with strategies to intensify the development of HIV-vaccines. INCO-projects and the formation of sizeable research clusters in the EU allowed strategies starting from molecular epidemiology to evaluation of vaccine candidates in primates and humans. Together with the Chinese Center for Disease Control early at onset of the HIV-epidemic in China relevant HIV-strains could be selected (B-clade RL42 and C-clade 97CN54, 97CN54 is a B -C recombinant and the most prevalent strain in Western and North-Western provinces of China). Using sequence modified genes from 97CN54 a set of immunogens comprising gag pol nef and env was developed which was found to be highly immunogenic but inactive in their original enzymatic functions. In context of the EUROVAC-cluster and the INCO-programme different presentation systems based amongst others DNA-plasmids (COBRA) and vaccinia viruses (NYVAC, MVA, TienTan) have been developed into GMP-manufactured products. These have been evaluated in parallel to the human trials in Rhesus monkeys. The combination of DNA prime vaccinia boost gave strong immune response in almost all animals in multiple HIV reading frames and on the basis of IFNα, IL-2 and IL-4 Elispots. Parallel experiments using the SHIV 89.6p-model showed protection from disease and rapid clearance of viremia to set point in challenge experiments. Data from human trials with NYVAC-C alone looked encouraging with 45 % responders, DNA alone did, upon first preliminary evaluation, not induce significant immune response jugged by CTL with about 10 % of the vaccinees. A trial with the combination of DNA-C prime and NYVAC-C boost parallels data in primates and achieved rigorous (Elispots above 400 up to 1200) broad (multiple antigens and epitopes), rigorous (multiple cytokines) and long lasting immunogenicity on almost all vaccinees (above 90 %). Further trials are up-coming in Regensburg and other European sites and in Beijing/China. 14

15 Virological monitoring of environmental matrices and food: importance for the risk assessment Annalaura Carducci, Dip. Biologia dell'università di Pisa The virological risk coming from the exposure to environmental contaminated matrices have characteristics that impose its specific consideration: viruses cannot be efficacy represented by the classic microbial indicators (i.e. E. Coli, enterococci and coliphages) because they have a lower infectious dose, multiple ways of transmission, different ecology in comparison with bacteria and a higher genetic variability often associated with the possibility of recombination. The recent examples of SARS and H5N1 avian influenza as well as studies on HEV, rotavirus and calicivirus, showed the importance of animal viruses in human pathology and the possible role of foods and environment as vehicle between infected and susceptible organisms: although viruses cannot multiply outside living cells, they can persist in the environment for a very long time because of their high resistance to natural and artificial disinfection agents and the protective action of environmental factors. The role of viruses as environmental biological risk agents has been proven by epidemiological data for different matrices: potable and recreational waters, food, arosol and surfaces. Unfortunately, in most cases, the epidemiological evidence has not been confirmed by the virus detection in the suspected matrices owing to the difficulties in applying to the environment analytical techniques developped for clinical materials. In fact, environmental samples have a highly variable composition often interfeering with the detection procedures, viruses are extremely diluted and multiple contamination of human and animal origin are frequent. Nevertheless, progress in clinical virology, in particular biomolecular techniques, and the development of methods for sample concentration and purification, have greatly improved the efficiency of virological analysis of environmental matrices and increased the amount of data on dectected viruses in waters, foods, aerosol, surfaces, etc. Although the majority of methods are still produced in house and need standardization, the virological environmental and food monitoring is now a real possibility and it can be useful for the risk analysis (assessment, control and communication) in different ways: to identify the routes of virus spreading, to verify the efficacy of control measures, to assess the level of sanitation thus helping the operators education, to monitor the environmental pollution, to carry out epidemiological surveillance of viral circulation, allowing molecular epidemiology and phylogenetic studies. The virological monitoring for the routine risk assessment of food and enviroment needs, besides the standardization of techniques, the selection of significant viral species and types or representative indicators and the clarification of the real meaning of the nucleic acid detection in the environment. Furtherly, monitoring data should be related to the clinical and surveillance ones to obtain quantitative information in terms of a dose-response relationship and probability of adverse outcomes. In conclusion, to use the environmental and food virology in the risk assessment, sharing knowledge and data with clinical human and veterinarian virologists will be an essential evolution. An emerging zoonosis: European bat lyssaviruses Franco Mutinelli, NRL for Rabies, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro (PD) In Europe, two bat lyssaviruses referred to as European bat lyssaviruses (EBLVs) types 1 and 2 (genotypes 5 and 6 respectively) which are closely related to classical rabies virus are responsible for an emerging zoonosis. EBLVs are host restricted to bats, and have been known to infect not only their primary hosts but also in rare circumstances, induce spillover infections to terrestrial mammals including domestic livestock, wildlife and man. Although spillover infections have occurred, there has been no evidence that the virus adapted to a new host. Since 1977, five human deaths from EBLVs have been reported. None of them had a record of prophylactic rabies immunization. Only fragmentary data exist about the effectiveness of current vaccines in cross-protection against EBLVs. EBLV in bats cannot be eliminated using conventional strategies similar to the control programmes based on vaccine baits used for fox rabies in Europe. Due to the protected status of bats in Europe, our knowledge of EBLV prevalence and epidemiology is limited. It is possible that EBLV is under-reported and that the recorded cases of EBLV represent only a small proportion of the actual number of infected bats. Human exposure through biting incidents, especially unprovoked attacks, should be treated immediately with rabies post-exposure treatment and the bat, where possible, retained for laboratory analysis and species identification. Preventative measures include educating all bat handlers of the risks posed by rabies-infected animals and advising them to be immunized. 15

16

17 General Virology and Viral Genetics 17

18

19 SELECTED ORAL COMMUNICATIONS Increasing circulation and diversification of HIV-1 non-b subtypes in Italy over a 10-year observation period Razzolini F, Saladini F, Vicenti I, Marconi A, Balestrieri M, Romano L, Zazzi M Department of Molecular Biology, University of Siena, Italy HIV-1 isolates belonging to the M (major) group are classified into subtypes (A, B, C, D, F, G, H, J, K), sub-subtypes (A1, A2, A3, F1, F2) and more than 30 circulating recombinant forms (CRFs). Geographic distribution of the different clades is subject to evolution over time as a result of human migration and settlement as well as possible preferential routes of transmission. HIV-1 pol sequence databases maintained at genotypic antiretroviral resistance testing reference laboratories can provide useful insights into the temporal changes in the circulation of HIV-1 clades. We analyzed clade assignment data stored at the HIV Monitoring Service of the University of Siena, Italy over a 10-year period ( ). More than 8000 HIV-1 sequences obtained from a total of 3485 patients were available. The first sequence of each patient was considered and assigned to the year of sampling. Subtyping was carried out by phylogenetic analysis using the Kimura distance model and neighbor-joining method with 1000-replicate bootstrap analysis. The overall prevalence of non-b subtypes in the data set was 10.4% and increased significantly over time reaching 29.8% in 2006 (p < ). A wide variety of subtypes and CRFs was represented, with subtypes A1, C, G, F1 and CRFs 01_AE and 02_AG each accounting for >5% of the pooled non-b sequences. Interestingly, as many as 9.4% (n = 34) of the non-b viruses were unique recombinant forms (URFs), particularly involving recombination between B and F subtypes. Significant association between individual highly represented subtypes and patient demographics were detected (e. g. CRF02_AG and African origin, decreased male-to-female ratio and clades A1, C, e CRF02_AG). Sequencing of additional HIV-1 regions (gag, env and in some cases full-length genome) for select strains allowed to characterize several complex and novel recombinant forms. The diversity of the HIV-1 sequence pool has increased significantly in recent years in Italy and will likely contribute to further exploration of HIV-1 genetic space at the population level. Detection and quantification of noroviruses in environmental samples by newly designed nested PCR assays and Taqman Real-Time RT-PCR. Muscillo, M., Pourshaban M., Fontana S., Di Grazia A., Iaconelli M., and La Rosa, G. Noroviruses have received increased attention in recent years because their role as etiologic agents in acute gastroenteritis outbreaks is now clearly established. In the present study, environmental samples from sea water, estuarine water, and effluents of sewage treatment plants were analyzed in order to evaluate the role of environmental surface contamination as a possible vehicle for transmission of norovirus genogroups I (GI) and II (GII). We used a previously published RT-PCR assay and also one that was developed in this study. The two assays resulted in similar detection, however with the new assay longer amplicons were obtained that provided more accurate phylogenetic assessment of the norovirus strains detected. To complete qualitative PCR assays, we performed quantitative RT-PCR (RT-Q-PCR) assays to detect norovirus concentrations in environmental samples by broadly reactive one-step TaqMan reverse transcription (RT)-PCR assays. Transcribed norovirus RNA from GI and GII plasmids were used as calibration curves. Quantitative data on the concentrations of noroviruses present in recreational water are indispensable for assessment of the public health risks caused by norovirus infections. While river, estuarine, and seawater samples were scarcely contaminated (0.9% of samples), all sewage samples were positive for norovirus GII; in 60% of samples both genogroup I and II were detected. This is the first study in Italy reporting the presence of Noroviruses in environmental samples not associated to evident outbreaks and outline the possible role played by water as a vehicle for transmission. 19

20 UL products are required for the activation of HCMV fusion complex during endothelial cell infection PATRONE Marco, MILANESI Gabriele and GALLINA Andrea University of Milano School of Medicine, Department of Medicine Surgery and Dentistry, Milano, Italy UL locus products are determinants of HCMV tropism for a number of cell types including leukocytes, DC and endothelial cells (EC) other than fibroblasts. The encoded proteins have been detected in the virion, complexed to envelope glycoproteins gh-gl, which suggests that UL polypeptides play role in viral entry. We have directly addressed this issue by comparing the fusion capability of an EC-tropic isolate (VR1814) with that of fibroblast-adapted strains. Indeed, all non-ec-tropic strains failed to fuse. The role of UL proteins in fusion was further proven by the ability of a recombinant pul128 (rpul128) to specifically inhibit VR1814 fusion with, and infection of, EC. Virion fusion was executed at the plasma membrane, as only fusion-deficient viral particles were found to be endocytosed. What is more, in VR1814 infections of EC we have characterized a post-attachment conformational intermediate of gb, the appearance of which is followed by a transient gb-gh interaction, detected in proximity of fusion. Both the gb intermediate and the gb-gh complex were inhibited by rpul128, and were absent in infections with non-ec-tropic strains. Altogether these findings indicate that UL products are required for the initiation of a chain of events triggering HCMV multi-component fusion machinery. Prevalence and Persistence of human papillomavirus genotypes and their variants in Human Immunodeficiency Virus (HIV) positive women from south-italy Maria Lina Tornesello 1, Maria Luisa Duraturo 1, Matilde Sansone 2, Roberto Piccoli 2, Luigi Buonaguro 1, Franco Maria Buonaguro 1,*, 1 Ist. Naz. Tumori "Fond. G. Pascale", Cappella Cangiani, I-80131, Naples, Italy, 2 Gynecology Department, University of Medicine, Naples, Italy Human immunodeficiency virus (HIV) positive women have high rates of infection with a broad range of human papillomavirus genotypes (HPV) whose oncogenic risk is not well known. Furthermore revalence and persistence of mucosal HPV genotypes have been analysed in 112 HIV-positive and 115 HIV-negative women during a 3-year followup period. Compared with HIV-negative, HIV-positive women were at the higher risk of HPV infection with a prevalence rate of 39.3% at the first visit and 43.7% after at least three visits. Among the twenty different viral genotypes identified the high risk HPVs (16, 18, 31, 33, 35, 45, 52, 58, and 66) were detected in 33% of HIV-positive and in 13% of HIV negative women, with the HPV16 as the most represented (16.1% and 6.9%) in both groups. Persistent infections with less characterized HPVs (45, 53, 54, 55, 61, 62, 70, 72, 81 and 83) were frequently found in HIV-positive women (within a range of 0.9%-16.3%) and significantly associated with low and high grade intraepithelial lesions. Phylogenetic analysis of HPV16 isolates allowed the identification of HPV16 African 2 and African 1 variants differently distributed in HIV-positive and HIV-negative women, suggesting different sexual mixing behaviours. The association of uncommon genotypes and variants with cytologic abnormalities in HIV-positive women underscores the need for targeting a wide range of HPV types in the screening analysis and in the design of future vaccines. 20

21 Polyomavirus BK and anti-dsdna antibodies in renal transplant recipients 1 Cristina Costa, 1 Massimiliano Bergallo, 2 Giovanni Antonio Touscoz, 1 Francesca Sidoti, 1 Maria Elena Terlizzi, 1 Sara Astegiano, 1 Chiara Merlino, 3 Giuseppe P. Segoloni, 1 Rossana Cavallo 1 Dept. of Public Health and Microbiology, Virology Unit, University of Turin, Italy 2 Gastro-Hepatology Unity, Laboratory of Digestive and Hepatic Physiopathology, and 3 Dept. of Internal Medicine, Renal Transplant Unit, Molinette Hospital, Turin, Italy Background. Polyomavirus BK reactivation is common in renal transplant recipients and may cause nephropathy with significant graft dysfunction. The induction of anti-dsdna antibodies by BKV has been described in experimental animals and during primary infection, and a role in the pathogenesis of systemic lupus erythematosus has been suggested. Methods. In this study we evaluated the occurrence of anti-dsdna antibodies and non-organ-specific autoantibodies by indirect immunofluorescence in 90 renal transplant recipients and the association with BKV reactivation as determined by BKV-DNA positivity on urine and/or serum samples. Results. Forty-four of 90 patients experienced a BKV reactivation; 17/90 developed anti-dsdna antibodies. Considering the 44 patients with BK viruria and/or viremia, anti-dsdna antibodies were present in 15 patients vs 29 who did not developed anti-dsdna antibodies, while in BKV DNA-negative patients 2 were anti-dsdna-positive vs 44 anti-dsdna-negative (p < 0.001). Considering the 22 patients with BK viremia (with or without viruria), anti-dsdna antibodies were present in 9 patients vs 13 who did not developed anti-dsdna antibodies, while in BK viremia-negative patients 8 were anti-dsdna positive vs 60 anti-dsdna negative (p < 0.01). No significant difference in terms of clinical parameters of renal function was found between anti-dsdna positive and negative patients. Conclusions. There is a significant association between BKV and production of anti-dsdna antibodies in renal transplant patients, however there is no evidence that these virus-induced autoreactive responses are themselves pathogenic. Inconsistent responses of cytomegalovirus-specific T-cells to pp65 and IE-1 vs infected dendritic cells in organ transplant recipients Daniele Lilleri 1, Paola Zelini 1, Chiara Fornara 1, Giuditta Comolli 1,2, Giuseppe Gerna 1 1 Servizio di Virologia, 2 Laboratori Sperimentali di Ricerca-Area Biotecnologie, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy CD4 + and CD8 + T-cells specific for human cytomegalovirus (HCMV) and two immunodominant HCMV antigens (pp65 and IE-1) were monitored in 20 solid organ transplant recipients undergoing primary (n=4) or reactivated (n=16) HCMV infection during the first year after transplantation by using as a stimulator either HCMV-infected autologous dendritic cells (DCs) or pp65- or IE-1 peptide mixtures. Turnaround times for test performance were 7 days for infected DCs and 24h for peptides. Using infected DCs, HCMV-specific T-cell restoration occurred in all patients for CD8 + and in 18/20 (90%) for CD4 + T-cell subpopulations, resulting in virus clearance from blood. Using peptide mixtures, T-cell responses were less frequently detected. In detail, 14 (70%) patients showed pp65-specific CD8 + T-cells and 10 (50%) patients IE-1-specific CD8 + T-cells, whereas pp65-specific CD4 + T-cells were detected in 14 (70%) patients, and IE-1- specific CD4 + T-cells in 3 (15%) patients only. Protection from HCMV infection was associated with the presence of a HCMV-specific T-cell response directed against multiple viral proteins, but not against pp65 or IE-1 only. In conclusion, the use of pp65 and IE-1 peptide mixtures for rapid monitoring of HCMV-specific T-cell responses in solid organ transplant recipients underestimates the actual level of protection against HCMV. 21

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models

More information

WHO Regional Office for Europe update on avian influenza A (H7N9) virus

WHO Regional Office for Europe update on avian influenza A (H7N9) virus WHO Regional Office for Europe update on avian influenza A (H7N9) virus Situation update 2: 30 April 2013 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO

More information

VIRUSES AND CANCER. Michael Lea

VIRUSES AND CANCER. Michael Lea VIRUSES AND CANCER 2012 Michael Lea VIRAL ONCOLOGY - LECTURE OUTLINE 1. Historical Review 2. Viruses Associated with Cancer 3. RNA Tumor Viruses 4. DNA Tumor Viruses HISTORICAL REVIEW Historical Review

More information

About Our Products. Blood Products. Purified Infectious/Inactivated Agents. Native & Recombinant Viral Proteins. DNA Controls and Primers for PCR

About Our Products. Blood Products. Purified Infectious/Inactivated Agents. Native & Recombinant Viral Proteins. DNA Controls and Primers for PCR About Our Products Purified Infectious/Inactivated Agents ABI produces a variety of specialized reagents, allowing researchers to choose the best preparations for their studies. Available reagents include

More information

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015 The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response

More information

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Molecular Diagnosis of Hepatitis B and Hepatitis D infections Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

Chapter 18: Applications of Immunology

Chapter 18: Applications of Immunology Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing

More information

Viruses. Viral components: Capsid. Chapter 10: Viruses. Viral components: Nucleic Acid. Viral components: Envelope

Viruses. Viral components: Capsid. Chapter 10: Viruses. Viral components: Nucleic Acid. Viral components: Envelope Viruses Chapter 10: Viruses Lecture Exam #3 Wednesday, November 22 nd (This lecture WILL be on Exam #3) Dr. Amy Rogers Office Hours: MW 9-10 AM Too small to see with a light microscope Visible with electron

More information

The public health risk of influenza in pigs recent insights, key knowledge gaps

The public health risk of influenza in pigs recent insights, key knowledge gaps The public health risk of influenza in pigs recent insights, key knowledge gaps Prof. Kristien Van Reeth Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Belgium H1N1, H3N2 and

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

Why use passive immunity?

Why use passive immunity? Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:

More information

The CVN Development Programme a 4-month update

The CVN Development Programme a 4-month update The CVN Development Programme a 4-month update Peter Simmonds Centre for Infectious Diseases University of Edinburgh Edinburgh CVN Development Programme Initiative announced in 2009 to focus development

More information

IMMUNOLOGY OF HIV INFECTION AND AIDS. Interactions between HIV and the immune system

IMMUNOLOGY OF HIV INFECTION AND AIDS. Interactions between HIV and the immune system IMMUNOLOGY OF HIV INFECTION AND AIDS Interactions between HIV and the immune system Basic Statistics United States In the U.S. in 2010, 1.1 million people were living with HIV infection. About 50,000 people

More information

Understanding the immune response to bacterial infections

Understanding the immune response to bacterial infections Understanding the immune response to bacterial infections A Ph.D. (SCIENCE) DISSERTATION SUBMITTED TO JADAVPUR UNIVERSITY SUSHIL KUMAR PATHAK DEPARTMENT OF CHEMISTRY BOSE INSTITUTE 2008 CONTENTS Page SUMMARY

More information

TOWARDS AN HIV VACCINE

TOWARDS AN HIV VACCINE why is it so hard to make an HIV vaccine and where are we now? Neal Nathanson, MD Emeritus Professor Department of Microbiology University of Pennsylvania School of Medicine 1 Estimated number of persons

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

BioMmune Technologies Inc. Corporate Presentation 2015

BioMmune Technologies Inc. Corporate Presentation 2015 BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical

More information

excerpted from Reducing Pandemic Risk, Promoting Global Health For the full report go to http://report.predict.global

excerpted from Reducing Pandemic Risk, Promoting Global Health For the full report go to http://report.predict.global excerpted from Reducing Pandemic Risk, Promoting Global Health For the full report go to http://report.predict.global FUTURE DIRECTIONS Historically, attempts to control deadly viruses, such as SARS and

More information

GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS

GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS -ii- GUIDELINES ON THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND

More information

Reconsideration Code 86386. Reconsideration Code Description Nuclear Matrix Protein 22 (NMP22), qualitative

Reconsideration Code 86386. Reconsideration Code Description Nuclear Matrix Protein 22 (NMP22), qualitative Calendar Year 2013 Centers for Medicare and Medicaid Services (CMS) New and Reconsidered Clinical Laboratory Fee Schedule (CLFS) Test Codes And Final Payment Determinations Reconsideration Code 86386 Reconsideration

More information

Cytomegalovirus (HHV5/CMV) Roseolovirus (HHV6 & 7)

Cytomegalovirus (HHV5/CMV) Roseolovirus (HHV6 & 7) Betaherpesvirinae Cytomegalovirus (HHV5/CMV) Roseolovirus (HHV6 & 7) CYTOMEGALOVIRUS CMV is thought to be amongst the oldest type of herpesvirus in evolutionary terms. CMV is the prototype of beta-herpesviruses

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or

More information

02/08/2010. 1. Background. Outline

02/08/2010. 1. Background. Outline Identification of immunodominant T-cell eptitopes in matrix protein of highly pathogenic porcine reproductive and respiratory syndrome virus Ya-Xin Wang, PhD Student Outline 1. Background 2. Research Contents

More information

TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS

TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAg AND PROVOKE HBsAg SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS Karine Lélu 1, Alexei Evlachev 1, Roland Kratzer 1, Sarah

More information

Basics of Immunology

Basics of Immunology Basics of Immunology 2 Basics of Immunology What is the immune system? Biological mechanism for identifying and destroying pathogens within a larger organism. Pathogens: agents that cause disease Bacteria,

More information

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

Biopharmaceutical Process Evaluated for Viral Clearance

Biopharmaceutical Process Evaluated for Viral Clearance Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate

More information

The Basics of Drug Resistance:

The Basics of Drug Resistance: CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu The Basics of Drug Resistance: QUESTIONS AND ANSWERS HIV Drug Resistance and ARV-Based Prevention 1. What is drug resistance?

More information

RNA Viruses. A Practical Approac h. Alan J. Cann

RNA Viruses. A Practical Approac h. Alan J. Cann RNA Viruses A Practical Approac h Alan J. Cann List of protocols page xiii Abbreviations xvii Investigation of RNA virus genome structure 1 A j. Easton, A.C. Marriott and C.R. Pringl e 1 Introduction-the

More information

http://www.who.int/csr/disease/avian_influenza/phase/en 4 http://new.paho.org/hq/index.php?option=com_content&task=view&id=1283&itemid=569

http://www.who.int/csr/disease/avian_influenza/phase/en 4 http://new.paho.org/hq/index.php?option=com_content&task=view&id=1283&itemid=569 Food and Agriculture Organization of the United Nations International Food Safety Authorities Network (INFOSAN) (Update) 30 April 2009 INFOSAN Information Note No. 2/2009 Human-animal interface aspects

More information

Viral Replication. Viral Replication: Basic Concepts

Viral Replication. Viral Replication: Basic Concepts Viral Replication Scott M. Hammer, M.D. Viral Replication: Basic Concepts Viruses are obligate intracellular parasites Viruses carry their genome (RNA or DNA) and sometimes functional proteins required

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER European Medicines Agency London 23 April 2009 EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR MEDICINAL

More information

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer

More information

Chapter 9. Biotechnology and Recombinant DNA Biotechnology and Recombinant DNA

Chapter 9. Biotechnology and Recombinant DNA Biotechnology and Recombinant DNA Chapter 9 Biotechnology and Recombinant DNA Biotechnology and Recombinant DNA Q&A Interferons are species specific, so that interferons to be used in humans must be produced in human cells. Can you think

More information

Interferon Fundamentals 2014

Interferon Fundamentals 2014 From Molecular Mechanisms to Human Diseases Rome, Auditorium Pocchiari Istituto Superiore di Sanità Over the last two decades, we have witnessed a tremendous progress in understanding the mechanisms by

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

Making the switch to a safer CAR-T cell therapy

Making the switch to a safer CAR-T cell therapy Making the switch to a safer CAR-T cell therapy HaemaLogiX 2015 Technical Journal Club May 24 th 2016 Christina Müller - chimeric antigen receptor = CAR - CAR T cells are generated by lentiviral transduction

More information

JIANGSU CARTMAY INDUSTRIAL CO.,LTD www.labfurniture.asia mail: info@labfurniture.asia

JIANGSU CARTMAY INDUSTRIAL CO.,LTD www.labfurniture.asia mail: info@labfurniture.asia The basic layout, the main functions and instrumentation concept of micro Inspection Division laboratory, 1, Virology Laboratory 1. Functions: for the city to monitor the prevalence of HIV disease, dealing

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

Autoimmunity and immunemediated. FOCiS. Lecture outline

Autoimmunity and immunemediated. FOCiS. Lecture outline 1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic

More information

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies

More information

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1: Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture

More information

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000

More information

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology

More information

SYMPOSIUM. June 15, 2013. Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Boston University

SYMPOSIUM. June 15, 2013. Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Boston University SYMPOSIUM June 15, 2013 Photonics Center Colloquium Room (906) 8 Saint Mary's St., Boston, MA 02215 Bette Korber Los Alamos National Labs HIV evolution and the neutralizing antibody response We have recently

More information

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics Page 1 IKDT Laboratory IKDT as Service Lab (CRO) for Molecular Diagnostics IKDT lab offer is complete diagnostic service to all external customers. We could perform as well single procedures or complex

More information

2) Macrophages function to engulf and present antigen to other immune cells.

2) Macrophages function to engulf and present antigen to other immune cells. Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components

More information

Production of antigens and antibodies in plants: alternative technology?

Production of antigens and antibodies in plants: alternative technology? Production of antigens and antibodies in plants: alternative technology? George Lomonossoff John Innes Centre Norwich, UK ECOPA, Alicante 29 th Sept. 2006 Why use Plants as Biofactories? Produce large

More information

CIBMTR Infection Data and the New Infection Inserts.

CIBMTR Infection Data and the New Infection Inserts. CIBMTR Infection Data and the New Infection Inserts. Marcie Tomblyn, MD, MS Scientific Director, CIBMTR Infection and Immune Reconstitution Working Committee Overview Indication for expanded data collection

More information

Connie Austin June 2012

Connie Austin June 2012 Rabies Exposures: When is Prophylaxis Recommended and Update on Communicable Disease Rule Changes Connie Austin June 2012 Rabies Transmission Bite from infected mammal (not birds, amphibians, reptiles)

More information

Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159. Date Submitted: 12-11-09

Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159. Date Submitted: 12-11-09 Title: Mapping T cell epitopes in PCV2 capsid protein - NPB #08-159 Investigator: Institution: Carol Wyatt Kansas State University Date Submitted: 12-11-09 Industry summary: Effective circovirus vaccines

More information

Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods

Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES PKS Chan 陳 基 湘 S Ma 文 子 光 SM Ngai 倪 世 明 Key Messages 1. Subjects recovered from SARS-CoV infection retain memory of cellular immune response to epitopes

More information

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae Ariela Benigni Biol.Sci.D., Ph.D. Curriculum Vitae Personal Data Name: Date and place of birth: Citizenship: E-mail: Ariela Benigni December 16, 1955 - Bergamo, Italy Italian ariela.benigni@marionegri.it

More information

The immunogenic vaccine against HCV and HBV

The immunogenic vaccine against HCV and HBV National Centre for Research and Development, The immunogenic vaccine against HCV and HBV Katarzyna Grzyb Laboratory of Virus Molecular Biology Intercollegate Faculty of Biotechnology UG-MUG 1 Hepatitis

More information

Principles of Disease and Epidemiology. Copyright 2010 Pearson Education, Inc.

Principles of Disease and Epidemiology. Copyright 2010 Pearson Education, Inc. Principles of Disease and Epidemiology Pathology, Infection, and Disease Disease: An abnormal state in which the body is not functioning normally Pathology: The study of disease Etiology: The study of

More information

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q5B INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE QUALITY OF BIOTECHNOLOGICAL PRODUCTS: ANALYSIS

More information

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works. November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also

More information

General presentation

General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology (NIRDMIC)

More information

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) 7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 44 credit hours: 1- Compulsory courses: 14 credit hours. 1504801, 1504802, 1504803,

More information

Diagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University

Diagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Diagnosis of HIV-1 Infection Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Tests Used to Diagnose HIV-1 Infection HIV antibody (today s topic) HIV p24 antigen HIV DNA HIV

More information

Activation and effector functions of HMI

Activation and effector functions of HMI Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ

More information

Solid Organ Transplantation

Solid Organ Transplantation Solid Organ Transplantation Infection Prevention And Control Transplant Atlantic 2011 October 13/2011 Kathy Hart Introduction In the past several years, the drugs that we use, the surgeries themselves,

More information

bitter is de pil Linos Vandekerckhove, MD, PhD

bitter is de pil Linos Vandekerckhove, MD, PhD 4//24 Current HIV care HIV copies/ ml plasma Viral load Welcome to the Digital droplet PCR age! bitter is de pil Linos Vandekerckhove, MD, PhD Latent HIV reservoir Time at Ghent University Hospital 2 HIV

More information

FACULTY OF MEDICAL SCIENCE

FACULTY OF MEDICAL SCIENCE Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression

More information

Luca Romagnoli, Ph.D. Business Development Manager

Luca Romagnoli, Ph.D. Business Development Manager Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies

More information

PATHOGENESIS OF AIDS

PATHOGENESIS OF AIDS Neal Nathanson, MD Emeritus Professor Department of Microbiology University of Pennsylvania School of Medicine 1 Definitions Structure of HIV HIV entry and cell tropism HIV-cell interactions Course of

More information

Veterinary Testing. Classes of Test

Veterinary Testing. Classes of Test Veterinary Testing Classes of Test July 2014 Copyright National Association of Testing Authorities, Australia 2014 This publication is protected by copyright under the Commonwealth of Australia Copyright

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY

More information

Hepatitis C Vaccines: Are we making progress?

Hepatitis C Vaccines: Are we making progress? Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify

More information

Rheumatoid arthritis: an overview. Christine Pham MD

Rheumatoid arthritis: an overview. Christine Pham MD Rheumatoid arthritis: an overview Christine Pham MD RA prevalence Chronic inflammatory disease affecting approximately 0.5 1% of the general population Prevalence is higher in North America (approaching

More information

Pharmacology skills for drug discovery. Why is pharmacology important?

Pharmacology skills for drug discovery. Why is pharmacology important? skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th

More information

European Medicines Agency

European Medicines Agency European Medicines Agency July 1996 CPMP/ICH/139/95 ICH Topic Q 5 B Quality of Biotechnological Products: Analysis of the Expression Construct in Cell Lines Used for Production of r-dna Derived Protein

More information

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.

More information

S I V PROGRAMME. 4 th National Congress of the Italian Society of Virology (SIV) Orvieto (TR), September 20-22, 2004

S I V PROGRAMME. 4 th National Congress of the Italian Society of Virology (SIV) Orvieto (TR), September 20-22, 2004 S I V Società Italiana di Virologia 4 th National Congress of the Italian Society of Virology (SIV) Orvieto (TR), September 20-22, 2004 PROGRAMME PROGRAMME September 20, 2004 14:00 - Opening session and

More information

RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE. Graduatoria e Finanziamento

RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE. Graduatoria e Finanziamento Direzione Generale Ricerca Scientifica e Tecnologica RICERCA FINALIZZATA+GIOVANI RICERCATORI MALATTIE RARE Graduatoria e Finanziamento Ministero della Salute Direzione Generale Ricerca Scientifica e Tecnologica

More information

Results Demographic profile of these children is shown in Table I.

Results Demographic profile of these children is shown in Table I. Prevalence of Antibody to Hepatitis C Virus in Pakistani Thalassaemics by Particle Agglutination Test Utilizing C 200 and C 22-3 Viral Antigen Coated Particles Pages with reference to book, From 269 To

More information

Scientific Programme

Scientific Programme Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico

More information

Recognition of T cell epitopes (Abbas Chapter 6)

Recognition of T cell epitopes (Abbas Chapter 6) Recognition of T cell epitopes (Abbas Chapter 6) Functions of different APCs (Abbas Chapter 6)!!! Directon Routes of antigen entry (Abbas Chapter 6) Flow of Information Barrier APCs LNs Sequence of Events

More information

Structure and Function of DNA

Structure and Function of DNA Structure and Function of DNA DNA and RNA Structure DNA and RNA are nucleic acids. They consist of chemical units called nucleotides. The nucleotides are joined by a sugar-phosphate backbone. The four

More information

Fabrizio Anniballi Alfonsina Fiore, Bruna Auricchio, Dario De Medici

Fabrizio Anniballi Alfonsina Fiore, Bruna Auricchio, Dario De Medici Fabrizio Anniballi Alfonsina Fiore, Bruna Auricchio, Dario De Medici Istituto Superiore di Sanità Department of Veterinary Public Health and Food Safety Unit of Microbiological Hazards National Reference

More information

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,

More information

Course Curriculum for Master Degree in Veterinary Epidemiology/Faculty of Veterinary Medicine

Course Curriculum for Master Degree in Veterinary Epidemiology/Faculty of Veterinary Medicine Course Curriculum for Master Degree in Veterinary Epidemiology/Faculty of Veterinary Medicine The Master Degree Veterinary Epidemiology/ Faculty of Veterinary Medicine is awarded by the Faculty of Graduate

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Fields of Education. Last updated August 2011

Fields of Education. Last updated August 2011 Fields of Education Last updated August 2011 Monash University is required to report to the Department of Education, Employment and Workplace Relations (DEEWR) the number of higher degree by research (HDR)

More information

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that

More information

Viral Hepatitis Case Report

Viral Hepatitis Case Report Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date

More information

1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.

1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors. Prof. Lester s BIOL 210 Practice Exam 4 (There is no answer key. Please do not email or ask me for answers.) Chapters 15, 16, 17, 19, HIV/AIDS, TB, Quorum Sensing 1) Siderophores are bacterial proteins

More information

Common Course Topics Biology 1414: Introduction to Biotechnology I

Common Course Topics Biology 1414: Introduction to Biotechnology I Common Course Topics Biology 1414: Introduction to Biotechnology I Assumptions Students may be enrolled in this course for several reasons; they are enrolled in the Biotechnology Program, they need a science

More information

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer

More information

Course Curriculum for Master Degree in Food Hygiene /Faculty of Veterinary Medicine

Course Curriculum for Master Degree in Food Hygiene /Faculty of Veterinary Medicine Course Curriculum for Master Degree in Food Hygiene /Faculty of Veterinary Medicine The Master Degree Food Hygiene /Veterinary Medicine is awarded by the Faculty of Graduate Studies at Jordan University

More information

Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency

Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency Guidance for Industry Antiviral Product Development Conducting and Submitting Virology Studies to the Agency U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

National Workshop of Hematology The TP53 Workshop

National Workshop of Hematology The TP53 Workshop National Workshop of Hematology The TP53 Workshop Bologna, 10 th May 2013 Aemilia Hotel Via G. Zaccherini Alvisi, 16 Bologna PROMOTED BY Workshop Presidents Michele Cavo Giovanni Martinelli Pier Luigi

More information

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:

More information

Understanding West Nile Virus Infection

Understanding West Nile Virus Infection Understanding West Nile Virus Infection The QIAGEN Bioinformatics Solution: Biomedical Genomics Workbench (BXWB) + Ingenuity Pathway Analysis (IPA) Functional Genomics & Predictive Medicine, May 21-22,

More information

Guidance. 2. Definitions. 1. Introduction

Guidance. 2. Definitions. 1. Introduction Work with naked DNA or RNA (including oligonucleotides, sirna, mirna, sequences that code for highly biologically active molecules and full length viral genomes) Guidance 1. Introduction The following

More information